2nd Annual MarketsandMarkets

Real-World Evidence and Market Access Conference

14th - 15th October 2024

Germany, Europe

Unlocking Insights, Driving Access: Bridging Real-World Evidence to Market Success in Europe

Join us at the MarketsandMarkets 2nd Annual Real-World Evidence and Market Access Conference, October 2024, Europe edition to be at the forefront of driving transformative change in healthcare.

This gathering serves a platform where industry leaders, healthcare professionals, and policymakers converge to explore the latest trends, challenges, and innovations shaping the dynamic landscape of evidence-based healthcare and market access strategies. Through engaging keynotes, interactive panel discussions, and networking opportunities, this event aims to foster collaboration, share best practices, and catalyze advancements that drive improved patient outcomes and successful market access across the European healthcare ecosystem.


  • Updates on European regulatory frameworks governing real-world evidence (RWE) and their impact on market access strategies.
  • Ensuring the reliability, validity, and relevance of RWE in the context of market access.
  • Effective collaboration strategies between industry stakeholders and payers to enhance market access outcomes.
  • Strategies for pricing and reimbursement that align with evidence-based market access approaches.
  • The impact of patient-reported outcomes on demonstrating product value and effectiveness.
  • The role of health economics in demonstrating the economic value of healthcare interventions.

  • Learn about the recent trends and advancements in Real-World Evidence Generation
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

  • Real-World Evidence
  • Real-World Data
  • Data Analytics
  • Health Economics & Outcomes Research- HEOR
  • Market Access/Value Access
  • Policy
  • Clinical Development & research
  • Clinical trial
  • Centre for Observational and Real-World Evidence  
  • Epidemiology
  • Oncology-RWE
  • Pricing and Reimbursement
  • Medical Affairs
  • Pharmacovigilance
  • Life Science Analytics
  • Big data
  • Data Science
  • Bio-Statistics
  • Consumer Healthcare


Payers, Regulators, Research Institutes, and Innovation Centre



08:15 - 09:00

Welcome note by MarketsandMarkets

09:00 - 09:05

Opening remarks by the Chairperson

09:05 - 09:10

Data Quality and Standardization

Ensuring the reliability and quality of real-world data used in RCTs.

09:10 - 09:40

Standardization and interoperability challenges in integrating diverse data sources

09:40 - 10:10

Sponsor Presentation - Slot Reserved for Gold/Platinum Sponsors

10:10 - 10:40

Morning Refreshments and Poster Presentation | One-to-One Networking Meeting

10:40 - 11:30

RWE for Health Technology Assessment (HTA)

Role of RWE in supporting HTA submissions

11:30 - 12:00

Addressing methodological challenges in RWE-based HTAs

12:00 - 12:30

Sponsor Presentation – Slot Reserved for Gold/Silver Sponsors

12:30 - 13:00

Lunch and Poster Presentation | One-to-One Networking

13:00 - 14:00

Post-Marketing Surveillance and Phase IV Trials

Leveraging real-world evidence for post-approval monitoring.

14:00 - 14:30

Sponsor Presentation – Slot Reserved for Silver/Bronze Sponsors

14:30 - 15:00

Panel Discussion- RWE in assessing long-term safety and effectiveness of interventions.

15:00 - 15:40

Evening Refreshments and Poster Presentation | One-to-One Networking

15:40 - 16:25

Patient Recruitment and Retention

Strategies for recruiting and retaining diverse patient populations

16:25 - 16:55

Closing remarks by the Chair Chairperson.

16:55 - 17:25

Drinks Reception and Networking .....END OF DAY 1.....

17:25 - 17:50


08:15 - 08:50

Welcome note by MarketsandMarkets

08:50 - 09:05

Opening remarks by the Chairperson

09:05 - 09:10

Patient-Centric Market Access

Utilizing patient-reported outcomes (PROs) and patient-centric RWE

09:10 - 09:40

Sponsor Presentation – Slot Reserved for Gold / Silver Sponsors

09:40 - 10:10

Engaging patients in the market access process

10:10 - 10:45

Morning Refreshments and Poster Presentation | One-to-One Networking

10:45 - 11:30

RWE in Market Access for Rare Diseases

Unique challenges and opportunities in demonstrating value for rare disease treatments

11:30 - 12:40

Sponsor Presentation – Slot Reserved for Bronze Sponsors

12:40 - 13:00

Navigating pricing and reimbursement considerations for orphan drugs

13:00 - 13:30

Closing remarks by the chairperson

13:30 - 13:35

Lunch and Poster Presentation | One-to-One Networking

13:35 - 13:35



13:35 - 13:35


Helene Vioix

Helene Vioix

Director Global Evidence & Value Development Oncology, Merck KGaA

Inha Kim

Inha Kim

Vice President, Head of Global Strategy and Communication, Medical Affairs,, Lundbeck

Vandana Ayyar-Gupta

Vandana Ayyar-Gupta

Scientific Adviser, Data & Analytics, National Institute for Health, and Care Excellence





Germany, Europe